News Kailera's big obesity reveal puts pressure on shares Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.
News Trial of Bundibugyo Ebola drugs starts in DRC Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.
News Newron charts course forward for stalled schizophrenia drug Newron thinks it may have reached an agreement with the FDA on a way to get the US development of its schizophrenia candidate evenamide back on track.
R&D Why are eCOA studies still so challenging? Although eCOA has been in clinical trials for decades, we continue to hit the same road blocks during operational set-up and implementation.
News Roche's KRAS drug tops its rivals in lung cancer trial Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.
News Despite study bust, Vistagen still hopes to file anxiety dru... Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.